IOVA
$13.62-7.47%
Iovance Biotherapeutics Inc.Stock · HealthcareRussell 2000 0.05%Nasdaq Composite 0.005%US Stock Market 0.002%Russell 3000 0.001%
IOVA financial statements
The full income statement, balance sheet, and cash-flow statement for Iovance Biotherapeutics Inc. (IOVA), plus valuation ratios — straight from SEC filings. Switch between annual, quarterly, and trailing-twelve-month figures, pick how far back to look, and flip the time order. Every line has a trend sparkline.
Shares outstanding (point-in-time)
2024-06 303.5M2024-09 304.8M2024-12 327.9M2025-03 333.9M2025-06 361.9M2025-09 397.0M2025-12 412.0M2026-03 446.5M2026-06 453.0M+49.2% over 8 periods
SEC-filed end-of-period counts (cover pages and balance sheets, split-adjusted) — the series realized buyback yield is computed from. The weighted-average share lines in the statements below lag these by design: an average over the year sits near the midpoint of an ongoing buyback.
As-reported fiscal years.
| Line item | Trend | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Income Statement | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| Revenue | 264M+60.6% | 164M+13699.0% | 1.19M | — | — | |
| Cost of revenue | 173M+85.7% | 93.2M+8926.9% | 1.03M | — | — | |
| — | — | — | 399M+16.4% | 343M+30.8% | ||
| Research & development | 300M+8.7% | 276M-17.1% | 333M+13.0% | 295M+13.8% | 259M+28.4% | |
| Selling, general & administrative | 152M+0.0% | 152M+43.5% | 106M+1.9% | 104M+24.4% | 83.7M+39.0% | |
| General & administrative | 152M+0.0% | 152M+43.5% | 106M+1.9% | 104M+24.4% | 83.7M+39.0% | |
| Restructuring | 5.14M | — | — | — | — | |
| Amortization of intangibles | 23.1M-12.5% | 26.4M+167.8% | 9.85M | 0.00 | — | |
| Operating income | -403M-2.0% | -395M+14.2% | -461M-15.5% | -399M-16.4% | -343M-30.8% | |
| Interest & investment income | 10.3M-49.2% | 20.3M+55.4% | 13.0M+337.0% | 2.98M+561.9% | 451K-80.9% | |
| Pre-tax income | -393M-4.8% | -375M+16.2% | -448M-13.0% | -396M-15.7% | -342M | |
| Income tax | -2.07M+26.8% | -2.83M+18.7% | -3.48M | 0.00 | 0.00 | |
| Net income | -391M-5.1% | -372M+16.2% | -444M-12.2% | -396M-15.7% | -342M-31.8% | |
| -$1.09+14.8% | -$1.28+32.3% | -$1.89+24.1% | -$2.49-11.7% | -$2.23-18.6% | ||
| EPS (basic) | -$1.09+14.8% | -$1.28+32.3% | -$1.89+24.1% | -$2.49-11.7% | -$2.23-18.6% | |
| Weighted-avg shares (basic) | 357M+23.3% | 290M+23.3% | 235M+47.6% | 159M+3.8% | 153M+10.9% | |
| Weighted-avg shares (diluted) | 357M+23.3% | 290M+23.3% | 235M+47.6% | 159M+3.8% | 153M+10.9% | |
| Balance Sheet | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| 443M-3.1% | 457M+48.5% | 308M-35.7% | 479M-5.7% | 508M-20.1% | ||
| Cash & equivalents | 163M+41.0% | 116M+0.7% | 115M-50.4% | 232M+196.2% | 78.2M+16.2% | |
| Short-term investments | 134M-35.7% | 208M+26.1% | 165M-31.3% | 240M-43.7% | 426M-24.2% | |
| Accounts receivable | 82.4M+18.9% | 69.3M+45820.5% | 151K | — | — | |
| Inventory | 51.7M+0.3% | 51.5M+396.7% | 10.4M | — | — | |
| Prepaid expenses | 11.6M-6.4% | 12.4M-29.1% | 17.5M+140.1% | 7.27M+105.0% | 3.55M-46.8% | |
| 913M+0.3% | 910M+16.7% | 780M+17.5% | 664M-14.6% | 777M+1.2% | ||
| Property, plant & equipment | 131M+20.2% | 109M-4.3% | 114M+8.4% | 105M+4.3% | 101M+70.6% | |
| Operating lease right-of-use | 45.9M-16.9% | 55.2M-11.7% | 62.5M-14.4% | 73.0M+5.8% | 69.0M+26.0% | |
| Intangible assets | 279M-1.1% | 282M+23.2% | 229M | — | — | |
| Long-term investments | — | — | — | — | 91.6M | |
| Other non-current assets | 8.17M+2113.0% | 369K+36.7% | 270K+42.9% | 189K-89.4% | 1.78M-86.2% | |
| 138M+13.1% | 122M+10.9% | 110M+20.6% | 91.5M+2.6% | 89.2M+62.6% | ||
| Accounts payable | 22.2M-19.4% | 27.5M-16.9% | 33.1M+24.5% | 26.6M-2.8% | 27.4M+102.6% | |
| Accrued liabilities | 111M+35.7% | 81.9M+18.1% | 69.4M+32.7% | 52.3M-7.9% | 56.8M+61.8% | |
| Current lease liability | 4.04M-68.6% | 12.9M+65.8% | 7.78M-38.2% | 12.6M+148.9% | 5.06M-19.5% | |
| 215M+7.3% | 200M+2.2% | 196M+19.1% | 164M+5.6% | 156M+39.0% | ||
| Non-current lease liability | 44.4M+0.1% | 44.4M-33.9% | 67.1M-6.6% | 71.9M+9.8% | 65.5M+44.3% | |
| Operating lease liability (total) | 48.4M-15.4% | 57.3M-23.5% | 74.9M-11.3% | 84.4M+19.7% | 70.5M+36.5% | |
| Deferred tax liabilities | 31.8M-1.5% | 32.3M+86.3% | 17.3M | — | — | |
| Total non-current liabilities | 76.2M-1.9% | 77.7M-9.1% | 85.4M+17.3% | 72.9M+9.6% | 66.5M+16.4% | |
| 699M-1.7% | 710M+21.5% | 585M+17.0% | 500M-19.6% | 622M-5.3% | ||
| Common stock | 17.0K+30.8% | 13.0K+18.2% | 11.0K+37.5% | 8.00K+14.3% | 7.00K+16.7% | |
| Additional paid-in capital | 3.46B+11.7% | 3.10B+19.3% | 2.59B+25.4% | 2.07B+15.3% | 1.79B+20.7% | |
| Retained earnings | -2.78B-16.4% | -2.38B-18.5% | -2.01B-28.3% | -1.57B-33.8% | -1.17B-41.2% | |
| Accumulated other comprehensive income | 16.4M+1671.7% | -1.05M-141.4% | 2.53M+380.0% | -902K-50.1% | -601K-3263.2% | |
| Total liabilities & equity | 913M+0.3% | 910M+16.7% | 780M+17.5% | 664M-14.6% | 777M+1.2% | |
| Common shares issued | 412M+35.0% | 305M+19.2% | 256M+36.4% | 188M+19.6% | 157M+6.9% | |
| Common shares outstanding | 412M+35.0% | 305M+19.2% | 256M+36.4% | 188M+19.6% | 157M+6.2% | |
| Shares outstanding (cover) | 412M+25.6% | 328M+17.4% | 279M+24.6% | 224M+42.7% | 157M+6.9% | |
| Cash Flow | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| -302M+14.3% | -353M+2.4% | -362M-23.6% | -293M-28.4% | -228M-11.1% | ||
| Depreciation & amortization | 12.9M+14.3% | 11.3M-2.7% | 11.6M+24.3% | 9.31M+199.3% | 3.11M+172.9% | |
| Intangible amortization | 23.1M-12.5% | 26.4M+167.8% | 9.85M | 0.00 | — | |
| Share-based compensation | 61.6M-43.8% | 110M+75.1% | 62.6M-25.5% | 84.0M+20.4% | 69.8M+70.6% | |
| Deferred income taxes | -2.07M+26.8% | -2.83M+18.7% | -3.48M | — | — | |
| Change in receivables | 13.1M-81.1% | 69.2M+46335.6% | 149K | — | — | |
| Change in inventory | 14.2M-68.0% | 44.4M+338.6% | 10.1M | — | — | |
| Change in payables | -6.66M+15.0% | -7.84M-262.4% | 4.83M-17.9% | 5.88M-15.7% | 6.98M+335.4% | |
| 47.5M+149.3% | -96.4M+37.9% | -155M-160.5% | 256M+194184.1% | 132K+100.0% | ||
| Capital expenditure | 33.8M+205.7% | 11.1M-50.3% | 22.3M+9.1% | 20.4M-45.6% | 37.6M-19.7% | |
| Free cash flow | -336M+7.6% | -364M+5.2% | -384M-22.6% | -313M-18.0% | -266M-5.4% | |
| Acquisitions | 0.00 | 0.00-100.0% | 213M | 0.00 | 0.00 | |
| 301M-23.0% | 391M-15.6% | 463M+143.5% | 190M-20.5% | 239M-58.5% | ||
| Long-term debt issued | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 1.00M | |
| Long-term debt repaid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Common stock issued | 306M-22.9% | 397M-14.2% | 463M+144.5% | 190M-6.7% | 203M-64.2% | |
| Common stock repurchased | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Dividends paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| FX effect on cash | 1.14M+311.5% | -541K+80.3% | -2.74M | — | — | |
| Net change in cash | 47.0M+179.3% | -59.3M-4.3% | -56.8M-136.9% | 154M+1242.6% | 11.5M | |
| Income taxes paid | 0.00 | 0.00 | 0.00 | — | — | |
| Valuation Ratios | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| Market cap | 1.12B-53.6% | 2.43B+16.6% | 2.08B+106.3% | 1.01B-66.4% | 3.00B-56.0% | |
| P/S | 4.3×-71.1% | 14.8× | — | — | — | |
| P/B | 1.6×-52.9% | 3.4×+10.6% | 3.1×+20.5% | 2.6×-46.9% | 4.8×-53.5% | |
| Source filing | 10-K | 10-K | 10-K | 10-K | 10-K |
About this data
Source: IOVA’s SEC filings (10-K / 10-Q). Annual columns are as-reported fiscal years; quarterly columns are as-reported fiscal quarters (Q4 derived as full-year minus the first three quarters where a company doesn’t file a standalone Q4); TTM (quarterly) rolls the trailing four quarters at every quarter end, TTM (yearly) samples that one year apart; balance-sheet rows show the period-end balance. Valuation ratios are sampled as of each period end. View all IOVA filings on SEC EDGAR → Not investment advice.